

Table A.2 Antimalarial drug policy, end 2004

Africa	<i>P. falciparum</i>					<i>P. vivax</i>	
	Uncomplicated		Treatment failure	Severe malaria	Pregnancy		
	Unconfirmed	Confirmed			Treatment	Prevention	
Central							
Cameroon	ASU+AQ*	ASU+AQ*	Q(7d)	Q(7d)		SP (IPT)	
CAR	CQ	CQ	SP	Q(7d)	Q(7d)	CQ weekly	
Chad	CQ	CQ	SP	Q(7d)		CQ weekly	
Congo	CQ	CQ	SP	Q(7d)		CQ weekly	
DR Congo	SP	SP	Q(7d)	Q(7d)		SP (IPT)	
Equatorial Guinea	CQ	CQ	Q(7d)	Q(7d)			
Gabon	ASU+AQ*	ASU+AQ*	ATM-LUM*	Q(7d)		SP (IPT)	
Sao Tome & Principe	ASU+AQ	ASU+AQ	Q(7d)	Q(7d)	Q or ASU+AQ	SP (IPT)	
East							
Burundi	ASU+AQ	ASU+AQ	Q(7d)	Q(7d)			
Comoros	ATM-LUM	ATM-LUM	Q(7d)	Q(7d)			
Djibouti	CQ	CQ	SP	Q(7d)	CQ		
Eritrea	CQ+SP	CQ+SP	Q(7d)	Q(7d)			CQ
Ethiopia	ATM-LUM	ATM-LUM	Q(7d)	Q(7d)			CQ
Kenya	ATM-LUM*	ATM-LUM*	Q(7d)	Q(7d)	Q(7d)	SP (IPT)	
Rwanda	AQ+SP	AQ+SP	Q(7d)	Q(7d)		SP (IPT)	
Somalia	CQ	CQ	SP	Q		SP (IPT)*	
Sudan	ASU+SP (North) ASU+AQ (South)	ASU+SP (North) ASU+AQ (South)	ATM-LUM (North) Q(7d) (South)	Q(7d) or ATM(6d) or ATM(3d)+ASU+SP (North)	Q(7d) or ASU+SP (from 13 weeks)	SP (IPT)	CQ+PQ(14d) (South)
Uganda	ATM-LUM*	ATM-LUM*	Q(7d)	Q(7d)	Q(7d)	SP (IPT)	
UR Tanzania	ATM-LUM* ASU+AQ (Zanzibar)	ATM-LUM* ASU+AQ (Zanzibar)	Q(7d) ATM-LUM (Zanzibar)	Q(7d)	SP	SP (IPT)	NA
North							
Algeria							CQ
Egypt	all confirmed	CQ+PQ	SP	Q(7d)			CQ+PQ(14d)
Morocco	all confirmed	ATM-LUM	Q(7d)	Q			CQ+PQ(14d)

Table A.2 Antimalarial drug policy, end 2004

Southern	<i>P. falciparum</i>				<i>P. vivax</i>	
	Uncomplicated		Treatment failure	Severe malaria	Pregnancy	
	Unconfirmed	Confirmed			Treatment	Prevention
Angola	CQ	CQ	SP	Q(7d)		CQ weekly
Botswana	SP	SP	Q(7d)	Q(7d)		
Madagascar	ASU+AQ*	ASU+AQ*	Q(7d)	Q(7d)		SP (IPT)
Malawi	SP	SP	Q(7d)	Q(7d)	SP or Q	SP (IPT)
Mauritius						CQ
Mozambique	AQ+SP	AQ+SP	ATM-LUM	Q(7d)		SP (IPT)
Namibia	ATM-LUM*	ATM-LUM*	Q(7d)	Q(7d)	Q	SP (IPT)
South Africa	ASU+SP (Mpumalaga)	ATM-LUM (KwaZulu Natal) ASU+SP (Mpumalaga)	Q(7d)	Q(7d)		CQ + PG (KwaZulu Natal)
Swaziland	CQ	CQ	SP	Q(7d)		
Zambia	ATM-LUM	ATM-LUM	Q(7d)	Q(7d)		SP (IPT)
Zimbabwe	CQ+SP	CQ+SP	Q(7d)	Q(7d)		SP (IPT)
West						
Benin	ATM-LUM*	ATM-LUM*	Q(7d)	Q(7d)		SP (IPT)
Burkina Faso	CQ	CQ	SP	Q(7d)	CQ	SP (IPT)
Cape Verde	CQ	CQ	SP	Q(7d)		CQ weekly
Côte d'Ivoire	AQ or SP	AQ or SP	ATM-LUM or AS+MQ	Q(7d)		SP (IPT)
Gambia	ATM-LUM*	ATM-LUM*	Q(7d)	Q(7d)		CQ weekly
Ghana	ASU+AQ*	ASU+AQ*	Q(7d)	Q(7d)	Q or ASU+AQ (2nd & 3rd trim.)	SP (IPT)
Guinea	CQ	CQ	SP	Q(7d)		SP (IPT)
Guinea-Bissau	CQ	CQ	SP	Q(7d)		SP (IPT)
Liberia	ASU+AQ	ASU+AQ	Q(7d)	Q(7d)		
Mali	ATM-LUM*	ATM-LUM*	ASU+SP	Q(7d)	Q(7d)	SP (IPT)
Mauritania	CQ	CQ	SP	Q(7d)		CQ weekly
Niger	ATM-LUM*	ATM-LUM*	Q(7d)	Q(7d)		CQ weekly
Nigeria	ATM-LUM*	ATM-LUM*	Q(7d)	Q(7d)	ACT (2nd & 3rd trim.)	SP (IPT)
Senegal	AQ+SP	AQ+SP	Q(7d)	Q(7d)		SP (IPT)
Sierra Leone	ASU+AQ	ASU+AQ	Q(7d)	Q(7d)		CQ weekly
Togo	CQ	CQ	SP	Q(7d)		SP (IPT)

Asia

Central Asia and Transcaucasia

	<i>P. falciparum</i>					<i>P. vivax</i>	
	Uncomplicated		Treatment failure	Severe malaria	Pregnancy		
	Unconfirmed	Confirmed			Treatment		Prevention
Nepal	CQ+PQ	SP+PQ	Q(7d)	Q(7d)	CQ	CQ+PQ	
Sri Lanka	CQ+PQ	CQ+PQ	SP+PQ	Q(7d)	CQ or Q	CQ+PQ	
Armenia	CQ	CQ+PQ	Q(7d)	Q(7d)	CQ	CQ+PQ(14d)	
Azerbaijan	CQ	CQ+PQ	Q(7d)	Q(7d)	CQ	CQ+PQ(14d)	
Georgia	CQ	CQ+PQ	Q(7d)	Q(7d)	CQ	CQ+PQ(14d)	
Kyrgyzstan	CQ	CQ+PQ	Q(7d)	Q(7d)	CQ	CQ+PQ(14d)	
Tajikistan	ASU(3d)+SP	ASU(3d)+SP	Q(7d)	Q(7d)	Q	CQ+PQ(14d)	
Turkmenistan	CQ	CQ+PQ	Q(7d)	Q(7d)	CQ	CQ+PQ(14d)	
Uzbekistan	CQ	CQ+PQ	Q(7d)	Q(7d)	CQ	CQ+PQ(14d)	

Eastern Mediterranean

Afghanistan	CQ+SP	ASU+SP*	Q(7d)	Q/ATM(7d)/(3d)+SP	Q or ASU+SP (Pf) CQ (Pv)	CQ
Iran (Islamic Republic of)	all confirmed	ASU+SP*	ATM–LUM	Q(7d) or ATM		CQ+PQ(14d)
Iraq	all confirmed					CQ+PQ(14d)
Oman	all confirmed	Q(3d)+SP+PQ(1d)	Q(7d)	Q	Q(7d)	CQ+PQ(14d)
Pakistan	CQ	CQ+PQ(3d)	SP	Q	CQ	CQ+PQ(5d)
Saudi Arabia	all confirmed	CQ	SP	Q		CQ+PQ(14d)
Syrian Arab Republic	all confirmed	SP	Q+D	Q(7d)		CQ+PQ(14d)
Turkey	CQ	CQ+PQ	Q(7d)	Q(7d)	CQ	CQ+PQ(14d)
United Arab Emirates	all confirmed	SP+PQ(3d)	MQ25	Q(7d)		CQ+PQ(14d)
Yemen	CQ	CQ	SP+PQ(1d)	Q+PQ(1d)	CQ	CQ+PQ(14d)

South-East Asia

Bangladesh	CQ+PQ	ATM–LUM	Q(7d)	Q(7d)	CQ or Q	NA	CQ+PQ(14d)
Bhutan		ATM–LUM*	Q(7d)	ATM inj (3d) or Q(7d)	Q(1st trim.) ASU(2nd & 3rd trim.)	CQ	CQ
DPR Korea							CQ+PQ
India	CQ ASU(3d)+SP (5 provinces)	CQ+PQ ASU(3d)+SP (5 provinces)	SP	Q(7d)	CQ	CQ	CQ+PQ
Indonesia	CQ+PQ	ASU(3d)+AQ	SP	Q(7d)	CQ	CQ	CQ+PQ(5d)
Maldives		CQ+PQ	MQ+SP	Q(5d)			CQ+PQ
Myanmar	CQ+SP or ASU(3d)+MQ	ATM–LUM or ASU+MQ	Q(7d)+D(7) or ASU(7d)+D(7)	Q(7d)+D(7) or ASU(7d)+D(7)	Q(1st trim.)+CD; ASU+C/D(2nd & 3rd trim.)+C/D	not recommended	CQ+PQ

Table A.2 Antimalarial drug policy, end 2004

	<i>P. falciparum</i>				<i>P. vivax</i>		
	Uncomplicated		Treatment failure	Severe malaria	Pregnancy		
	Unconfirmed	Confirmed			Treatment	Prevention	
Thailand	NA	MQ (alone) or MQ+ASU(2d)	Q(7d)+T(7d)	ASU or Q	Q(7d)	NA	CQ+PQ
Timor-Leste	CQ+SP	SP	Q(7d)	Q(7d)			CQ+PQ
Western Pacific							
Cambodia	ASU(3d)+MQ	ASU(3d)+MQ	Q(7d)+T(7d)	ATM(IM)+MQ	Q(7d)or ASU+MQ		CQ
China	CQ/ATM(5d)/DHA (Yunnan, Hainan)	ATM/ASU(5d)/DHA (Yunnan, Hainan)	ATM/ASU(7d).Q/PYR (Yunnan, Hainan)	ATM (Yunnan, Hainan) or QC	Q(7d)/CQ (Yunnan, Hainan)		CQ+PQ(8d)
Lao PDR	CQ+SP	CQ+SP or ATM-LUM	Q(7d)+D/T(7d)	Q(7d)+D/T(7d)	Q (Pf) and CQ (Pv)	NA	CQ
Malaysia	all confirmed	CQ/SP/CQ+SP(day3) +/- PQ(3d)	Q(7)+T(7) or MQ	Q(7d)	Q(7d)	CQ weekly	CQ+PQ(14d)
Papua New Guinea	CQ / AQ+SP	CQ / AQ+SP	ASU(7d)+SP	ATM(7d)+SP	CQ or Q	CQ	CQ+PQ(14d)* or CQ+SP+PQ
Philippines	CQ+SP+PQ	CQ+SP+PQ	ATM-LUM	Q(7d)+T	CQ+SP	CQ	CQ+PQ(14d)
Republic of Korea							CQ+PQ(14d)
Solomon Islands	CQ or CQ+SP	CQ+SP	Q(3d) + SP	Q(7d)	CQ+SP	CQ	CQ+PQ(14d) or CQ+SP+PQ
Vanuatu	CQ	CQ +SP	Q(7d)	Q(7d)	CQ+SP	CQ	CQ+PQ
Viet Nam	ASU(5d) or CQ	DHA/PPQ/TMP+PQ or ASU(5d)+PQ	DHA/PPQ/TMP+PQ ASU(3d)+MQ25	ASU/ATM or Q	Q(7d) or CQ or ASU	CQ (weekly)	CQ+PQ(5d)

The Americas

Central America & Caribbean

Belize							CQ+PQ
Costa Rica							CQ+PQ
Dominican Republic		CQ+ PQ(3d)					
El Salvador							CQ+PQ
Guatemala							CQ+PQ
Haiti		CQ+PQ					
Honduras							CQ+PQ
Mexico							CQ+PQ
Nicaragua							CQ+PQ
Panama							CQ+PQ

South America	<i>P. falciparum</i>					<i>P. vivax</i>	
	Uncomplicated		Treatment failure	Severe malaria	Pregnancy		
	Unconfirmed	Confirmed			Treatment		Prevention
Argentina						CQ+PQ	
Bolivia		MQ15+ASU(3d) CQ + PQ	Q(7d) + C(7d) MQ15/25+ASU			CQ+PQ	
Brazil		Q(3d)+D(5d) +PQ(day6) Q(3d)+D(5d)+PQ (Amazon)	MQ15/20+PQ(day2) MQ15/20+PQ (Amazon)	ASU vs ATM or Q	Q (Pf) or CQ (Pv)	CQ+PQ(7d)	
Colombia		AQ(3d)+SP+PQ	Q(3d)+C20(5d) MQ(3rd line)		AQ (Pf)	CQ+PQ	
Ecuador		ASU+SP	Q Q(7d)+T/C/D(7d) (3rd line)			CQ+PQ	
French Guiana		Q(7d)+T(7d)				CQ+PQ	
Guyana		ATM–LUM	Q(7d)+T(7d)			CQ+PQ	
Paraguay		CQ+ PQ				CQ+PQ	
Peru		ASU(3d)+MQ (in 1 province) ASU(3d)+SP				CQ+PQ	
Suriname		ATM–LUM	Q(7d)			CQ+PQ	
Venezuela		ASU+MQ	Q(7d)+T/C/D(7d)			CQ	

* = policy adopted, not presently being deployed, implementation process ongoing